Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Prednisone
Drug: Vincristine
Drug: Doxorubicin
Drug: PEG-asparaginase
Drug: Cytarabine
Drug: Methotrexate
Drug: Imatinib
Drug: Clofarabine
Drug: 6 Mercaptopurine

First Posted Date: 2009-09-09

Last Posted Date: 2017-03-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT00973752

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage II Non-Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate
Drug: Vorinostat

First Posted Date: 2009-09-07

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 83

Registration Number: NCT00972478

Locations: 🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸
Doctors Hospital, Columbus, Ohio, United States

and more 187 locations

Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis

Not Applicable

Conditions: Focal Segmental Glomerulosclerosis

Interventions: Drug: prednisone, FK506, MMF
Drug: prednisone

First Posted Date: 2009-08-11

Last Posted Date: 2009-08-11

Lead Sponsor: Health Science Center of Xi'an Jiaotong University

Target Recruit Count: 40

Registration Number: NCT00956059

Locations: 🇨🇳
The second affiliated hospital of medical college, Xi'an Jiaotong University, Xi'an, Shaanxi, China

Pomalidomide for Myelofibrosis Patients

Phase 2

Completed

Conditions: Polycythemia Vera
Thrombocythemia

Interventions: Drug: CC-4047
Drug: Prednisone

First Posted Date: 2009-07-24

Last Posted Date: 2019-06-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT00946270

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Metastatic Prostate Cancer

Interventions: Drug: Bevacizumab
Drug: Lenalidomide
Drug: Docetaxel
Drug: Prednisone

First Posted Date: 2009-07-21

Last Posted Date: 2018-10-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT00942578

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Polycystic Liver Disease in Kidney Transplant

Not Applicable

Terminated

Conditions: Polycystic Liver Disease

Interventions: Drug: Sirolimus
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Prednisone

First Posted Date: 2009-07-08

Last Posted Date: 2013-03-08

Lead Sponsor: Mayo Clinic

Target Recruit Count: 2

Registration Number: NCT00934791

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Phase 2

Completed

Conditions: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

Interventions: Drug: Rituximab
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2009-07-02

Last Posted Date: 2017-01-11

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 206

Registration Number: NCT00931918

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸
Georgia Cancer Specialists, Atlanta, Georgia, United States

and more 67 locations